Interneurons, tau and amyloid-β in the piriform cortex in Alzheimer’s disease

Brain Structure and Function

Volumn 220, Issue 4, 2015, Pages 2011-2025

  Saiz Sanchez, Daniel ^a   De la Rosa Prieto, Carlos ^a   Ubeda Banon, Isabel ^a   Martinez Marcos, Alino ^a  

^a University of Castilla La Mancha   (Spain)

Author keywords

Amyloid ; Human brain; Hyposmia; Piriform cortex; Somatostatin; Tau

Indexed keywords

AMYLOID BETA PROTEIN; CALRETININ; PARVALBUMIN; PEROXIDASE; SOMATOSTATIN; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITE; ENTORHINAL CORTEX; ENZYME ACTIVITY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INTERNEURON; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PYRAMIDAL NERVE CELL; PYRIFORM CORTEX; AGED; CELL COUNT; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CALBINDIN 2; CELL COUNT; FEMALE; HUMANS; INTERNEURONS; MALE; MIDDLE AGED; PARVALBUMINS; PIRIFORM CORTEX; SOMATOSTATIN; TAU PROTEINS;

EID: 84933178343     PISSN: 18632653     EISSN: 18632661     Source Type: Journal    
DOI: 10.1007/s00429-014-0771-3     Document Type: Article

References (104)

1. Arzi A, Sobel N (2011) Olfactory perception as a compass for olfactory neural maps. Trends Cogn Sci 15:537–545. doi:10.1016/j.tics.2011.09.007
2. Attems J, Lintner F, Jellinger KA (2005) Olfactory involvement in aging and Alzheimer’s disease: an autopsy study. J Alzheimers Dis 7:149–157 (discussion 173–180)
3. Attems J, Preusser M, Grosinger-Quass M, Wagner L, Lintner F, Jellinger K (2008) Calcium-binding protein secretagogin-expressing neurones in the human hippocampus are largely resistant to neurodegeneration in Alzheimer’s disease. Neuropathol Appl Neurobiol 34:23–32. doi:10.1111/j.1365-2990.2007.00854.x
4. Benarroch EE (2010) Olfactory system: functional organization and involvement in neurodegenerative disease. Neurology 75:1104–1109. doi:10.1212/WNL.0b013e3181f3db84
5. Bezprozvanny I, Mattson MP (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci 31:454–463. doi:10.1016/j.tins.2008.06.005
6. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259
7. Braak H, Del Tredici K (2011) Alzheimer’s pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol 121:589–595. doi:10.1007/s00401-011-0825-z
8. Braak H, Braak E, Bohl J, Bratzke H (1998) Evolution of Alzheimer’s disease related cortical lesions. J Neural Transm Suppl 54:97–106
9. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211. [pii]: S0197458002000659
10. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404. doi:10.1007/s00401-006-0127-z
11. Brady DR, Mufson EJ (1997) Parvalbumin-immunoreactive neurons in the hippocampal formation of Alzheimer’s diseased brain. Neuroscience 80:1113–1125
12. Burgos-Ramos E, Hervas-Aguilar A, Aguado-Llera D, Puebla-Jimenez L, Hernandez-Pinto AM, Barrios V et al (2008) Somatostatin and Alzheimer’s disease. Mol Cell Endocrinol 286:104–111. doi:10.1016/j.mce.2008.01.014
13. Burns A (2000) Might olfactory dysfunction be a marker of early Alzheimer’s disease? Lancet 355:84–85. doi:10.1016/S0140-6736(99)90402-6
14. Buxbaum JD, Thinakaran G, Koliatsos V, O’Callahan J, Slunt HH, Price DL et al (1998) Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J Neurosci 18:9629–9637
15. Cao L, Schrank BR, Rodriguez S, Benz EG, Moulia TW, Rickenbacher GT et al (2012) Abeta alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo. Nat Commun 3:1009. doi:10.1038/ncomms2013
16. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A et al (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11:909–913. doi:10.1038/ncb1901
17. Davies P, Katzman R, Terry RD (1980) Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature 288:279–280
18. Davis KL, Davidson M, Yang RK, Davis BM, Siever LJ, Mohs RC et al (1988) CSF somatostatin in Alzheimer’s disease, depressed patients, and control subjects. Biol Psychiatry 24:710–712
19. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ et al (2012) Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 73:685–697. doi:10.1016/j.neuron.2011.11.033
20. Devanand DP, Michaels-Marston KS, Liu X, Pelton GH, Padilla M, Marder K et al (2000) Olfactory deficits in patients with mild cognitive impairment predict Alzheimer’s disease at follow-up. Am J Psychiatry 157:1399–1405
21. Djordjevic J, Jones-Gotman M, De Sousa K, Chertkow H (2008) Olfaction in patients with mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 29:693–706. doi:10.1016/j.neurobiolaging.2006.11.014
22. Doty RL (2008) The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann Neurol 63:7–15. doi:10.1002/ana.21327
23. Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H et al (2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330:980–982. doi:10.1126/science.1194516
24. Epelbaum J, Guillou JL, Gastambide F, Hoyer D, Duron E, Viollet C (2009) Somatostatin, Alzheimer’s disease and cognition: an old story coming of age? Prog Neurobiol 89:153–161. doi:10.1016/j.pneurobio.2009.07.002
25. Esiri MM, Wilcock GK (1984) The olfactory bulbs in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 47:56–60
26. Filali M, Lalonde R (2009) Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer’s disease. Brain Res 1292:93–99. doi:10.1016/j.brainres.2009.07.066
27. Florio T (2008) Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 13:822–840
28. Fonseca M, Soriano E (1995) Calretinin-immunoreactive neurons in the normal human temporal cortex and in Alzheimer’s disease. Brain Res 691:83–91. [pii]: 0006-8993(95)00622-W
29. Fotuhi M, Hachinski V, Whitehouse PJ (2009) Changing perspectives regarding late-life dementia. Nat Rev Neurol 5:649–658. doi:10.1038/nrneurol.2009.175
30. Goedert M, Spillantini MG (2006) A century of Alzheimer’s disease. Science 314:777–781. doi:10.1126/science.1132814
31. Gottfried JA, Deichmann R, Winston JS, Dolan RJ (2002) Functional heterogeneity in human olfactory cortex: an event-related functional magnetic resonance imaging study. J Neurosci 22:10819–10828
32. Hama E, Saido TC (2005) Etiology of sporadic Alzheimer’s disease: somatostatin, neprilysin, and amyloid beta peptide. Med Hypotheses 65:498–500. doi:10.1016/j.mehy.2005.02.045
33. Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G et al (2011) alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Investig 121:715–725. doi:10.1172/JCI43366
34. Harris JA, Devidze N, Verret L, Ho K, Halabisky B, Thwin MT et al (2010) Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal–hippocampal network. Neuron 68:428–441. doi:10.1016/j.neuron.2010.10.020
35. Hawkes C, Doty RL (2009) The neurology of olfaction. Cambridge University Press, Cambridge
36. Hawkes CH, Del Tredici K, Braak H (2007) Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 33:599–614. doi:10.1111/j.1365-2990.2007.00874.x
37. Heizmann CW, Braun K (1992) Changes in Ca(2+)-binding proteins in human neurodegenerative disorders. Trends Neurosci 15:259–264. [pii]: 0166-2236(92)90067-I
38. Hernandez F, Avila J (2008) Tau aggregates and tau pathology. J Alzheimers Dis 14:449–452
39. Hof PR, Morrison JH (1991) Neocortical neuronal subpopulations labeled by a monoclonal antibody to calbindin exhibit differential vulnerability in Alzheimer’s disease. Exp Neurol 111:293–301
40. Hof PR, Cox K, Young WG, Celio MR, Rogers J, Morrison JH (1991) Parvalbumin-immunoreactive neurons in the neocortex are resistant to degeneration in Alzheimer’s disease. J Neuropathol Exp Neurol 50:451–462
41. Hof PR, Nimchinsky EA, Celio MR, Bouras C, Morrison JH (1993) Calretinin-immunoreactive neocortical interneurons are unaffected in Alzheimer’s disease. Neurosci Lett 152:145–148
42. Howard JD, Plailly J, Grueschow M, Haynes JD, Gottfried JA (2009) Odor quality coding and categorization in human posterior piriform cortex. Nat Neurosci 12:932–938. doi:10.1038/nn.2324
43. Iacopino AM, Christakos S (1990) Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci USA 87:4078–4082
44. Iritani S, Niizato K, Emson PC (2001) Relationship of calbindin D28K-immunoreactive cells and neuropathological changes in the hippocampal formation of Alzheimer’s disease. Neuropathology 21:162–167
45. Kato HK, Gillet SN, Peters AJ, Isaacson JS, Komiyama T (2013) Parvalbumin-expressing interneurons linearly control olfactory bulb output. Neuron 80:1218–1231. doi:10.1016/j.neuron.2013.08.036
46. Kjelvik G, Evensmoen HR, Brezova V, Haberg AK (2012) The human brain representation of odor identification. J Neurophysiol. doi:10.1152/jn.01036.2010
47. Kovacs T, Cairns NJ, Lantos PL (1999) Beta-amyloid deposition and neurofibrillary tangle formation in the olfactory bulb in ageing and Alzheimer’s disease. Neuropathol Appl Neurobiol 25:481–491. [pii]: nan208
48. Leinwand SG, Chalasani SH (2011) Olfactory networks: from sensation to perception. Curr Opin Genet Dev 21:806–811. doi:10.1016/j.gde.2011.07.006
49. Leuba G, Kraftsik R, Saini K (1998) Quantitative distribution of parvalbumin, calretinin, and calbindin D-28k immunoreactive neurons in the visual cortex of normal and Alzheimer cases. Exp Neurol 152:278–291. doi:10.1006/exnr.1998.6838
50. Li W, Howard JD, Gottfried JA (2010) Disruption of odour quality coding in piriform cortex mediates olfactory deficits in Alzheimer’s disease. Brain 133:2714–2726. doi:10.1093/brain/awq209
51. Mai JK, Paxinos G, Voss T (2008) Atlas of the human brain. Elsevier, New York
52. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E et al (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313:1781–1784. doi:10.1126/science.1131864
53. Mikkonen M, Alafuzoff I, Tapiola T, Soininen H, Miettinen R (1999) Subfield- and layer-specific changes in parvalbumin, calretinin and calbindin-D28K immunoreactivity in the entorhinal cortex in Alzheimer’s disease. Neuroscience 92:515–532. [pii]: S0306-4522(99)00047-0
54. Miyamichi K, Amat F, Moussavi F, Wang C, Wickersham I, Wall NR et al (2011) Cortical representations of olfactory input by trans-synaptic tracing. Nature 472:191–196. doi:10.1038/nature09714
55. Miyamichi K, Shlomai-Fuchs Y, Shu M, Weissbourd BC, Luo L, Mizrahi A (2013) Dissecting local circuits: parvalbumin interneurons underlie broad feedback control of olfactory bulb output. Neuron 80:1232–1245. doi:10.1016/j.neuron.2013.08.027
56. Mount C, Downton C (2006) Alzheimer disease: progress or profit? Nat Med 12:780–784. doi:10.1038/nm0706-780
57. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G et al (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050–4058
58. Nelson PT, Braak H, Markesbery WR (2009) Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 68:1–14. doi:10.1097/NEN.0b013e3181919a48
59. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362–381. doi:10.1097/NEN.0b013e31825018f7
60. Nestor PJ, Scheltens P, Hodges JR (2004) Advances in the early detection of Alzheimer’s disease. Nat Med 10(Suppl):S34–S41. doi:10.1038/nrn1433nrn1433
61. Ni H, Huang L, Chen N, Zhang F, Liu D, Ge M et al (2010) Upregulation of barrel GABAergic neurons is associated with cross-modal plasticity in olfactory deficit. PLoS ONE 5:e13736. doi:10.1371/journal.pone.0013736
62. Nilsson CL, Brinkmalm A, Minthon L, Blennow K, Ekman R (2001) Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer’s disease and frontotemporal dementia. Peptides 22:2105–2112
63. Ohm TG, Braak H (1987) Olfactory bulb changes in Alzheimer’s disease. Acta Neuropathol 73:365–369
64. Palop JJ, Mucke L (2010) Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci 13:812–818. doi:10.1038/nn.2583
65. Palop JJ, Jones B, Kekonius L, Chin J, Yu GQ, Raber J et al (2003) Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer’s disease-related cognitive deficits. Proc Natl Acad Sci USA 100:9572–9577. doi:10.1073/pnas.1133381100
66. Palop JJ, Chin J, Mucke L (2006) A network dysfunction perspective on neurodegenerative diseases. Nature 443:768–773. doi:10.1038/nature05289
67. Perrin RJ, Fagan AM, Holtzman DM (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature 461:916–922. doi:10.1038/nature08538
68. Poo C, Isaacson JS (2009) Odor representations in olfactory cortex: “sparse” coding, global inhibition, and oscillations. Neuron 62:850–861. doi:10.1016/j.neuron.2009.05.022
69. Poo C, Isaacson JS (2011) A major role for intracortical circuits in the strength and tuning of odor-evoked excitation in olfactory cortex. Neuron 72:41–48. doi:10.1016/j.neuron.2011.08.015
70. Price JL, Morris JC (2004) So what if tangles precede plaques? Neurobiol Aging 25:721–723. doi:10.1016/j.neurobiolaging.2003.12.017 (discussion 743–746)
71. Price JL, Davis PB, Morris JC, White DL (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer’s disease. Neurobiol Aging 12:295–312
72. Roman G, Pascual B (2012) Contribution of neuroimaging to the diagnosis of Alzheimer’s disease and vascular dementia. Arch Med Res 43:671–676. doi:10.1016/j.arcmed.2012.10.018
73. Rowe CC, Villemagne VL (2013) Amyloid imaging with PET in early Alzheimer disease diagnosis. Med Clin N Am 97:377–398. doi:10.1016/j.mcna.2012.12.017
74. Rubio A, Sanchez-Mut JV, Garcia E, Velasquez ZD, Oliver J, Esteller M et al (2012) Epigenetic control of somatostatin and cortistatin expression by beta amyloid peptide. J Neurosci Res 90:13–20. doi:10.1002/jnr.22731
75. Runyan CA, Schummers J, Van Wart A, Kuhlman SJ, Wilson NR, Huang ZJ et al (2010) Response features of parvalbumin-expressing interneurons suggest precise roles for subtypes of inhibition in visual cortex. Neuron 67:847–857. doi:10.1016/j.neuron.2010.08.006
76. Saito T, Iwata N, Tsubuki S, Takaki Y, Takano J, Huang SM et al (2005) Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 11:434–439. doi:10.1038/nm1206
77. Saiz-Sanchez D, Ubeda-Banon I, de la Rosa-Prieto C, Argandona-Palacios L, Garcia-Munozguren S, Insausti R et al (2010) Somatostatin, tau, and beta-amyloid within the anterior olfactory nucleus in Alzheimer disease. Exp Neurol 223:347–350. doi:10.1016/j.expneurol.2009.06.010
78. Saiz-Sanchez D, Ubeda-Banon I, de La Rosa-Prieto C, Martinez-Marcos A (2012) Differential expression of interneuron populations and correlation with amyloid-deposition in the olfactory cortex of an APP/PS1 transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis 30:1–17
79. Saiz-Sanchez D, De La Rosa-Prieto C, Ubeda-Banon I, Martinez-Marcos A (2013) Interneurons and beta-amyloid in the olfactory bulb, anterior olfactory nucleus and olfactory tubercle in APPxPS1 transgenic mice model of Alzheimer’s disease. Anat Rec (Hoboken) 296:1413–1423. doi:10.1002/ar.22750
80. Sampson VL, Morrison JH, Vickers JC (1997) The cellular basis for the relative resistance of parvalbumin and calretinin immunoreactive neocortical neurons to the pathology of Alzheimer’s disease. Exp Neurol 145:295–302. doi:10.1006/exnr.1997.6433
81. Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766
82. Serby M, Richardson SB, Twente S, Siekierski J, Corwin J, Rotrosen J (1984) CSF somatostatin in Alzheimer’s disease. Neurobiol Aging 5:187–189
83. Sheng JG, Price DL, Koliatsos VE (2002) Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Abeta amyloidosis. J Neurosci 22:9794–9799
84. Small SA, Duff K (2008) Linking Abeta and tau in late-onset Alzheimer’s disease: a dual pathway hypothesis. Neuron 60:534–542. doi:10.1016/j.neuron.2008.11.007
85. Solodkin A, Veldhuizen SD, Van Hoesen GW (1996) Contingent vulnerability of entorhinal parvalbumin-containing neurons in Alzheimer’s disease. J Neurosci 16:3311–3321
86. Sosulski DL, Bloom ML, Cutforth T, Axel R, Datta SR (2011) Distinct representations of olfactory information in different cortical centres. Nature 472:213–216. doi:10.1038/nature09868
87. Stettler DD, Axel R (2009) Representations of odor in the piriform cortex. Neuron 63:854–864. doi:10.1016/j.neuron.2009.09.005
88. Suzuki N, Bekkers JM (2010) Inhibitory neurons in the anterior piriform cortex of the mouse: classification using molecular markers. J Comp Neurol 518:1670–1687. doi:10.1002/cne.22295
89. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580. doi:10.1002/ana.410300410
90. Tsuboi Y, Wszolek ZK, Graff-Radford NR, Cookson N, Dickson DW (2003) Tau pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4. Neuropathol Appl Neurobiol 29:503–510. [pii]: 453
91. Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL et al (2011) Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res 89:1031–1042. doi:10.1002/jnr.22640
92. Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K et al (2012) Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149:708–721. doi:10.1016/j.cell.2012.02.046
93. Vickers JC, Dickson TC, Adlard PA, Saunders HL, King CE, McCormack G (2000) The cause of neuronal degeneration in Alzheimer’s disease. Prog Neurobiol 60:139–165. [pii]: S0301008299000234
94. Viollet C, Lepousez G, Loudes C, Videau C, Simon A, Epelbaum J (2008) Somatostatinergic systems in brain: networks and functions. Mol Cell Endocrinol 286:75–87. doi:10.1016/j.mce.2007.09.007
95. Wang J, Eslinger PJ, Doty RL, Zimmerman EK, Grunfeld R, Sun X et al (2010) Olfactory deficit detected by fMRI in early Alzheimer’s disease. Brain Res 1357:184–194. doi:10.1016/j.brainres.2010.08.018
96. Wesson DW, Levy E, Nixon RA, Wilson DA (2010) Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer’s disease mouse model. J Neurosci 30:505–514. doi:10.1523/JNEUROSCI.4622-09.2010
97. Wesson DW, Borkowski AH, Landreth GE, Nixon RA, Levy E, Wilson DA (2011) Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer’s beta-amyloidosis mouse model. J Neurosci 31:15962–15971. doi:10.1523/JNEUROSCI.2085-11.2011
98. Wilson DA, Sullivan RM (2011) Cortical processing of odor objects. Neuron 72:506–519. doi:10.1016/j.neuron.2011.10.027
99. Wilson RS, Arnold SE, Schneider JA, Boyle PA, Buchman AS, Bennett DA (2009) Olfactory impairment in presymptomatic Alzheimer’s disease. Ann N Y Acad Sci 1170:730–735. doi:10.1111/j.1749-6632.2009.04013.x
100. Wood PL, Etienne P, Lal S, Gauthier S, Cajal S, Nair NP (1982) Reduced lumbar CSF somatostatin levels in Alzheimer’s disease. Life Sci 31:2073–2079
101. Wu N, Rao X, Gao Y, Wang J, Xu F (2013) Amyloid-beta deposition and olfactory dysfunction in an Alzheimer’s disease model. J Alzheimers Dis 37:699–712. doi:10.3233/JAD-122443
102. Young JW, Sharkey J, Finlayson K (2009) Progressive impairment in olfactory working memory in a mouse model of mild cognitive impairment. Neurobiol Aging 30:1430–1443. doi:10.1016/j.neurobiolaging.2007.11.018
103. Zelano C, Sobel N (2005) Humans as an animal model for systems-level organization of olfaction. Neuron 48:431–454. doi:10.1016/j.neuron.2005.10.009
104. Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C et al (2011) Soluble Abeta levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer’s disease. Behav Brain Res 222:342–350. doi:10.1016/j.bbr.2011.03.072